Gijsbert Veerman

1.2k citations
16 papers · 1.1k · h-index 12

Impact in

  • Oncology top 5%
    • Pancreatic and Hepatic Oncology Research
  • Genetics top 10%
    • Chronic Lymphocytic Leukemia Research

Papers in

  • Molecular Biology 12
    • Cancer therapeutics and mechanisms 6
    • DNA Repair Mechanisms 5
    • Biochemical and Molecular Research 5
  • Oncology 10
    • Colorectal Cancer Treatments and Studies 4
    • Cancer Treatment and Pharmacology 3
    • Cancer-related Molecular Pathways 3
Co-authors
Godefridus J. Peters (16 shared papers)Veronique W.T. Ruiz van Haperen (13 shared papers)Jan B. Vermorken (7 shared papers)Herbert M. Pinedo (9 shared papers)Epie Boven (3 shared papers)Paul Noordhuis (3 shared papers)Kees Smid (4 shared papers)Andries M. Bergman (5 shared papers)
Journals
Biochemical Pharmacology (6 papers)Advances in experimental medicine and biology (4 papers)The International Journal of Biochemistry & Cell Biology (1 paper)European Journal of Cancer (1 paper)Cancer Chemotherapy and Pharmacology (1 paper)
Partner nations
NetherlandsUnited StatesSweden

In The Last Decade

Gijsbert Veerman

16 papers receiving 1.0k citations

Peers

Gijsbert Veerman
Comparison fields: 5 of 72
  • Oncology 567
  • Genetics 141
  • Cancer Research 137
  • Infectious Diseases 149
  • Physiology 36
Replace Veronique W.T. Ruiz van Haperen with:
Veronique W.T. Ruiz van Haperen Netherlands
Daphne Voorn Netherlands
Willem J.P Loves Netherlands
Billie Nowak United States
D. M. Moccio United States
Rosemary Kimbell United Kingdom
Sara Nannizzi Italy
WS Dalton United States
Julian A. Marin‐Acevedo United States
Amy Kramer United States
Gijsbert Veerman relative to Veronique W.T. Ruiz van Haperen Netherlands Veronique W.T. Ruiz van Haperen's profile →
Citations per field
00.5×1.5×
Veronique W.T. Ruiz van Haperen · 1×
Citations per year

Countries citing papers authored by Gijsbert Veerman

Since Specialization
Citations

This map shows the geographic impact of Gijsbert Veerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gijsbert Veerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gijsbert Veerman more than expected).

Fields of papers citing papers by Gijsbert Veerman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gijsbert Veerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gijsbert Veerman. The network helps show where Gijsbert Veerman may publish in the future.

Co-authors

The 25 scholars most cited alongside Gijsbert Veerman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gijsbert Veerman Line = papers co-authored together Gijsbert Veerman links everyone, so they are left out of the graph.

All Works

16 of 16 papers shown
#Work
1
2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
Biochemical Pharmacology ·Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Jan B. Vermorken, Godefridus J. Peters
1993220
2
In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant
Cancer Research ·Andries M. Bergman, Paul P. Eijk, Veronique W.T. Ruiz van Haperen, Kees Smid, Gijsbert Veerman, Isabelle Hubeek, Paul van den IJssel, Bauke Ylstra, Godefridus J. Peters
2005163
3
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
PubMed ·Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, S. Eriksson, Epie Boven, Alexander P.A. Stegmann, Mario Hermsen, Jan B. Vermorken, Herbert M. Pinedo, Godefridus J. Peters
1994157
4
Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours
Biochemical Pharmacology ·Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Epie Boven, Paul Noordhuis, Jan B. Vermorken, Godefridus J. Peters
1994117
5
Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors
Cancer Chemotherapy and Pharmacology ·Gijsbert Veerman, Veronique W.T. Ruiz van Haperen, Jan B. Vermorken, Paul Noordhuis, Boudewijn J.M. Braakhuis, Herbert M. Pinedo, Godefridus J. Peters
199689
6
Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase
Biochemical Pharmacology ·Andries M. Bergman, Herbert M. Pinedo, A.P.M. Jongsma, Marjoleine Brouwer, Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, A. Leyva, Steffan Eriksson, Godefridus J. Peters
199970
7
Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine
Biochemical Pharmacology ·Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Jan B. Vermorken, Herbert M. Pinedo, Godefridus J. Peters
199668
8
Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts
European Journal of Cancer ·Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Boudewijn J.M. Braakhuis, Jan B. Vermorken, Epie Boven, A. Leyva, Godefridus J. Peters
199353
9
Inhibition of thymidylate synthase by 2′,2′-difluoro-2′-deoxycytidine (Gemcitabine) and its metabolite 2′,2′-difluoro-2′-deoxyuridine
The International Journal of Biochemistry & Cell Biology ·Richard J. Honeywell, Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Kees Smid, Godefridus J. Peters
201542
10
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines
Biochemical Pharmacology ·C.J.A. van Moorsel, Herbert M. Pinedo, Gijsbert Veerman, Assen Guechev, Kees Smid, Willem J.P Loves, Jan B. Vermorken, Pieter E. Postmus, Godefridus J. Peters
199937
11
Collateral sensitivity to gemcitabine (2′,2′-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines11Abbreviations: ara-C,1-β-d-arabinofuranosylcytosine; dCDA, deoxycytidinedeaminase; dCK, deoxycytidine kinase; dCyd, deoxycytidine; dFdC,2′,2′-difluorodeoxycytidine; MDR, multidrug resistance; MRP,multidrug resistance-associated protein; P-gP, P-glycoprotein; SCLC,small cell lung carcinoma; TCA, trichloroacetic acid; TK, thymidinekinase; and VM-26, teniposide, epipodophyllotoxin 4′-demethyl-O-(4,6-O-2-thenylidene-β-d-glucopyranoside).
Biochemical Pharmacology ·Andries M. Bergman, Birgitte Munch‐Petersen, Peter Buhl Jensen, Maxwell Sehested, Gijsbert Veerman, Daphne Voorn, Kees Smid, Herbert M. Pinedo, Godefridus J. Peters
200126
12
Synergistic Interaction between Cisplatin and Gemcitabine in Ovarian and Colon Cancer Cell Lines
Advances in experimental medicine and biology ·(unknown), Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Catharina M. Kuiper, Godefridus J. Peters
199515
13
Concentration and Time Dependent Growth Inhibition and Metabolism in vitro by 2’,2’-Difluoro-Deoxycytidine (Gemcitabine)
Advances in experimental medicine and biology ·Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Paul Noordhuis, Jan B. Vermorken, Godefridus J. Peters
199111
14
Increased Sensitivity to Gemcitabine of P-gP and MRP Overexpressing Human Non-Small Cell Lung Cancer Cell Lines
Advances in experimental medicine and biology ·Andries M. Bergman, Herbert M. Pinedo, Gijsbert Veerman, Catharina M. Kuiper, Godefridus J. Peters
199810
15
Cross-Resistance of the Gemcitabine Resistant Human Ovarian Cancer Cell Line AG6000 to Standard and Investigational Drugs
Advances in experimental medicine and biology ·Andries M. Bergman, Herbert M. Pinedo, Veronique W.T. Ruiz van Haperen, Gijsbert Veerman, Catharina M. Kuiper, Godefridus J. Peters
19984
16
Three-Dimensional Cell Cultures as a Model System to Evaluate the Biological Activity of Gemcitabine (2', 2'-Difluoro-2'deoxycytidine)
Nucleosides Nucleotides & Nucleic Acids ·Godefridus J. Peters, Evelien Smitskamp-Wilms, Gijsbert Veerman, Paulo Pizao, Veronique W.T. Ruiz van Haperen, Herbert M. Pinedo
19953

About Gijsbert Veerman

Gijsbert Veerman is a scholar working on Molecular Biology, Oncology, Infectious Diseases, Cancer Research and Genetics, having authored 16 papers that have together received 1.1k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (6 papers), DNA Repair Mechanisms (5 papers), Biochemical and Molecular Research (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (3 papers), Cancer-related Molecular Pathways (3 papers), HIV/AIDS drug development and treatment (3 papers) and Acute Myeloid Leukemia Research (2 papers). The work is most often cited by research in Oncology (567 citations), Genetics (141 citations), Cancer Research (137 citations), Infectious Diseases (149 citations) and Physiology (36 citations). Gijsbert Veerman has collaborated with scholars based in Netherlands, United States and Sweden. Frequent co-authors include Godefridus J. Peters, Veronique W.T. Ruiz van Haperen, Jan B. Vermorken, Herbert M. Pinedo, Epie Boven, Paul Noordhuis, Kees Smid, Andries M. Bergman, Boudewijn J.M. Braakhuis and Bauke Ylstra. Their work appears in journals such as Biochemical Pharmacology, Advances in experimental medicine and biology, The International Journal of Biochemistry & Cell Biology, European Journal of Cancer and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Veronique W.T. Ruiz van HaperenBreakdown of academic impact, for papers by Daphne VoornBreakdown of academic impact, for papers by Willem J.P LovesBreakdown of academic impact, for papers by Billie NowakBreakdown of academic impact, for papers by D. M. MoccioBreakdown of academic impact, for papers by Rosemary KimbellBreakdown of academic impact, for papers by Sara NannizziBreakdown of academic impact, for papers by WS DaltonBreakdown of academic impact, for papers by Julian A. Marin‐AcevedoBreakdown of academic impact, for papers by Amy Kramer